

Sharon A Chung

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9760866/publications.pdf>

Version: 2024-02-01

43
papers

3,923
citations

257450
24
h-index

276875
41
g-index

44
all docs

44
docs citations

44
times ranked

4799
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of Systemic Lupus Erythematosus with <i>C8orf13</i> and <i>ITGAM</i> . New England Journal of Medicine, 2008, 358, 900-909.	27.0	848
2	A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nature Genetics, 2009, 41, 1228-1233.	21.4	729
3	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis and Rheumatology, 2021, 73, 1366-1383.	5.6	249
4	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis and Rheumatology, 2021, 73, 1349-1365.	5.6	231
5	Differential Genetic Associations for Systemic Lupus Erythematosus Based on Anti-dsDNA Autoantibody Production. PLoS Genetics, 2011, 7, e1001323.	3.5	206
6	Specificity of the STAT4 Genetic Association for Severe Disease Manifestations of Systemic Lupus Erythematosus. PLoS Genetics, 2008, 4, e1000084.	3.5	180
7	Risk Alleles for Systemic Lupus Erythematosus in a Large Case-Control Collection and Associations with Clinical Subphenotypes. PLoS Genetics, 2011, 7, e1001311.	3.5	154
8	A Comprehensive Analysis of Shared Loci between Systemic Lupus Erythematosus (SLE) and Sixteen Autoimmune Diseases Reveals Limited Genetic Overlap. PLoS Genetics, 2011, 7, e1002406.	3.5	148
9	Lupus Nephritis Susceptibility Loci in Women with Systemic Lupus Erythematosus. Journal of the American Society of Nephrology: JASN, 2014, 25, 2859-2870.	6.1	117
10	High-Density SNP Screening of the Major Histocompatibility Complex in Systemic Lupus Erythematosus Demonstrates Strong Evidence for Independent Susceptibility Regions. PLoS Genetics, 2009, 5, e1000696.	3.5	109
11	Microscopic Polyangiitis. Rheumatic Disease Clinics of North America, 2010, 36, 545-558.	1.9	106
12	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Care and Research, 2021, 73, 1088-1105.	3.4	90
13	<i>PTPN22</i> : Its role in SLE and autoimmunity. Autoimmunity, 2007, 40, 582-590.	2.6	77
14	Analysis of pulmonary features and treatment approaches in the COPA syndrome. ERJ Open Research, 2018, 4, 00017-2018.	2.6	71
15	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Care and Research, 2021, 73, 1071-1087.	3.4	61
16	Genome-wide profiling identifies associations between lupus nephritis and differential methylation of genes regulating tissue hypoxia and type 1 interferon responses. Lupus Science and Medicine, 2016, 3, e000183.	2.7	54
17	DNA methylation 101: what is important to know about DNA methylation and its role in SLE risk and disease heterogeneity. Lupus Science and Medicine, 2018, 5, e000285.	2.7	52
18	Genome-Wide Assessment of Differential DNA Methylation Associated with Autoantibody Production in Systemic Lupus Erythematosus. PLoS ONE, 2015, 10, e0129813.	2.5	51

#	ARTICLE	IF	CITATIONS
19	Genetic contributions to lupus nephritis in a multi-ethnic cohort of systemic lupus erythematosus patients. PLoS ONE, 2018, 13, e0199003.	2.5	46
20	A phenotypic and genomics approach in a multi-ethnic cohort to subtype systemic lupus erythematosus. Nature Communications, 2019, 10, 3902.	12.8	39
21	Sequence-Based Screening of Patients With Idiopathic Polyarteritis Nodosa, Granulomatosis With Polyangiitis, and Microscopic Polyangiitis for Deleterious Genetic Variants in <i>ADA2</i>. Arthritis and Rheumatology, 2021, 73, 512-519.	5.6	34
22	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa. Arthritis and Rheumatology, 2021, 73, 1384-1393.	5.6	32
23	Advances in the use of biologic agents for the treatment of systemic vasculitis. Current Opinion in Rheumatology, 2009, 21, 3-9.	4.3	31
24	European population substructure is associated with mucocutaneous manifestations and autoantibody production in systemic lupus erythematosus. Arthritis and Rheumatism, 2009, 60, 2448-2456.	6.7	27
25	Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study. American Journal of Human Genetics, 2021, 108, 84-99.	6.2	26
26	Primary Angiitis of the Central Nervous System. Rheumatic Disease Clinics of North America, 2017, 43, 503-518.	1.9	24
27	Giant Cell Arteritis: A Systematic Review and Meta-Analysis of Test Accuracy and Benefits and Harms of Common Treatments. ACR Open Rheumatology, 2021, 3, 429-441.	2.1	20
28	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa. Arthritis Care and Research, 2021, 73, 1061-1070.	3.4	15
29	Rare variants, autoimmune disease, and arthritis. Current Opinion in Rheumatology, 2016, 28, 346-351.	4.3	13
30	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease. Arthritis Care and Research, 2022, 74, 538-548.	3.4	13
31	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease. Arthritis and Rheumatology, 2022, 74, 586-596.	5.6	13
32	Eosinophilic Granulomatosis with Polyangiitis: A Systematic Review and Meta-Analysis of Test Accuracy and Benefits and Harms of Common Treatments. ACR Open Rheumatology, 2021, 3, 101-110.	2.1	12
33	Granulomatosis With Polyangiitis and Microscopic Polyangiitis: A Systematic Review and Meta-Analysis of Benefits and Harms of Common Treatments. ACR Open Rheumatology, 2021, 3, 196-205.	2.1	10
34	Takayasu Arteritis: a Systematic Review and Meta-Analysis of Test Accuracy and Benefits and Harms of Common Treatments. ACR Open Rheumatology, 2021, 3, 80-90.	2.1	9
35	Polyarteritis Nodosa: A Systematic Review of Test Accuracy and Benefits and Harms of Common Treatments. ACR Open Rheumatology, 2021, 3, 91-100.	2.1	6
36	Current Treatment of Cryoglobulinemic Vasculitis. Current Treatment Options in Rheumatology, 2016, 2, 213-224.	1.4	5

#	ARTICLE	IF	CITATIONS
37	Dynamics of Methylation of <scp>CpG</scp> Sites Associated With Systemic Lupus Erythematosus Subtypes in a Longitudinal Cohort. Arthritis and Rheumatology, 2022, 74, 1676-1686.	5.6	5
38	Endovascular Therapy for Intracranial Giant Cell Arteritis. Clinical Neuroradiology, 2022, , 1.	1.9	4
39	Neurological manifestations of polyarteritis nodosa: a tour of the neuroaxis by case series. BMC Neurology, 2021, 21, 205.	1.8	3
40	Kawasaki Disease: A Systematic Review and Metaâ€Analysis of Benefits and Harms of Common Treatments. ACR Open Rheumatology, 2021, 3, 671-683.	2.1	2
41	149â€...Network-based analysis of clinical and molecular data in a multiethnic lupus cohort identifies molecular associations with serological manifestations. , 2019, , .		0
42	Reply. Arthritis and Rheumatology, 2022, 74, 545-546.	5.6	0
43	The Right Frame. Journal of Hospital Medicine, 2019, 14, 246.	1.4	0